To assess the associations of semaglutide with incident AUD (first time diagnosis of AUD), the study population included 83,825 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new-user design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (naltrexone, topiramate, bupropion, orlistat, phentermine) 54 during 6/202112/2022 (time zero or index event), had no diagnosis of AUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which gives it a slightly different mechanism of action than semaglutide's single-target approach
Effect of glucagon-like peptide-2 exposure on bone resorption: effectiveness of high concentration versus prolonged exposure
By enhancing collagen and elastin production in the dermis, they can thicken the skin and increase firmness
During training, monthly or seasonal Vitamin B12 injections can be considered to keep you energized, sharp and increase stamina during training